CIViC Compass
Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.

CIViC Evidence Items

4766 evidence items indexed

Evidence Level Distribution

CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).

AValidated — meta-analysis, systematic review, or major guideline
BClinical — prospective trial or retrospective cohort study
CCase study — single case report or small case series
DPreclinical — in vitro or animal model data
EInferential — computational prediction or biological rationale

Gene × Evidence Type

Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.

PredictiveDiagnosticPrognosticFunctionalPredispos.Oncogenic
BCR::ABL132311
BRAF18642621
EGFR2481232
EML4::ALK64
ERBB21422
FLT355221
KIT10237
KRAS1594244
PIK3CA156164
PTEN5313121
TP5352401002
VHL52363515
Predictive:Links a variant to treatment response or resistance
Diagnostic:Supports or refutes a specific disease diagnosis
Prognostic:Informs disease progression or clinical outcome
Functional:Characterises the biological effect of a variant
Predisposing:Germline variant associated with cancer predisposition
Oncogenic:Characterises the variant's role in oncogenesis
LevelGeneVariantTypeDirectionSignificanceDiseaseDrugsSource
BERBB2AmplificationPredictiveSupportsSensitivity/ResponseGastric AdenocarcinomaLapatinibSatoh et al., 2014
Av::ROS1FusionPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaCrizotinibMazières et al., 2015
BHIF1AOVEREXPRESSIONPrognosticSupportsPoor OutcomeColorectal CancerBaba et al., 2010
BEPAS1OverexpressionPrognosticDoes Not SupportPoor OutcomeColorectal CancerBaba et al., 2010
DVHLLossPredictiveSupportsSensitivity/ResponseRenal CarcinomaTemsirolimusThomas et al., 2006
DFLT3D835PredictiveSupportsResistanceAcute Myeloid LeukemiaQuizartinib,PonatinibSmith et al., 2013
DFLT3D835PredictiveSupportsResistanceAcute Myeloid LeukemiaSU5614von Bubnoff et al., 2009
BERBB2AmplificationPredictiveDoes Not SupportSensitivity/ResponseLung Non-small Cell CarcinomaTrastuzumabLara et al., 2004
CERBB2G778_P780dupPredictiveSupportsSensitivity/ResponseLung AdenocarcinomaDacomitinibKris et al., 2015
BNEDD9EXPRESSIONPrognosticSupportsPoor OutcomeHepatocellular CarcinomaLi et al., 2016
BFGF13CYTOPLASMIC EXPRESSIONPrognosticSupportsPoor OutcomeProstate CancerYu et al., 2016
BSS18::SSX1FusionDiagnosticSupportsPositiveSynovial SarcomaKawai et al., 1998
BSS18::SSX2FusionDiagnosticSupportsPositiveSynovial SarcomaKawai et al., 1998
BSS18::SSX2FusionPrognosticSupportsBetter OutcomeSynovial SarcomaKawai et al., 1998
BSS18::SSX1FusionPrognosticSupportsPoor OutcomeSynovial SarcomaKawai et al., 1998
BSS18::SSX1FusionDiagnosticSupportsPositiveMalignant Peripheral Nerve Sheath TumorO'Sullivan et al., 2000
BSS18::SSX2FusionPrognosticSupportsBetter OutcomeSynovial SarcomaLadanyi et al., 2002
BABCB1S893A/TPrognosticSupportsBetter OutcomeBreast CancerKim et al., 2012
BABCB1I1145IPrognosticSupportsBetter OutcomeBreast CancerKim et al., 2012
DEGFRK467TPredictiveSupportsSensitivity/ResponseColorectal CancerFutuximab/Modotuximab Mixture,PanitumumabSánchez-Martín et al., 2016
DEGFRK467TPredictiveSupportsResistanceColorectal CancerCetuximabSánchez-Martín et al., 2016
BFCGR2AH167RPrognosticDoes Not SupportBreast CancerKim et al., 2012
BFCGR3AF212VPrognosticDoes Not SupportBreast CancerKim et al., 2012
CEGFRP753SPredictiveSupportsSensitivity/ResponseSkin Squamous Cell CarcinomaSirolimus,CetuximabGanesan et al., 2016
CPML::RARAFusion AND PML L218PPredictiveSupportsResistanceAcute Promyelocytic LeukemiaTretinoinGoto et al., 2011
CMETAmplification AND MET Splice Site (c.3028G>A)PredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaCrizotinibAwad et al., 2016
DSMOD473HPredictiveSupportsSensitivity/ResponseMedulloblastomaPatidegibLee et al., 2012
DROS1G2032R AND CD74::ROS1 FusionPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaCabozantinibKatayama et al., 2015
DCEBPAN-TERMINAL FRAME SHIFTPredictiveSupportsSensitivity/ResponseAcute Myeloid LeukemiaOICR-9429Grebien et al., 2015
DFGFR1AmplificationPredictiveSupportsResistanceBreast CancerAfimoxifeneTurner et al., 2010
DKDRA1065TPredictiveSupportsSensitivity/ResponseAngiosarcomaSunitinib,SorafenibAntonescu et al., 2009
DKDRD717VPredictiveSupportsSensitivity/ResponseAngiosarcomaSunitinib,SorafenibAntonescu et al., 2009
BFLT3ITDPrognosticSupportsPoor OutcomeAcute Promyelocytic LeukemiaHong et al., 2011
BALDH1A2OverexpressionPrognosticSupportsBetter OutcomeHead And Neck Squamous Cell CarcinomaSeidensaal et al., 2015
BALDH1A2OverexpressionPrognosticSupportsBetter OutcomeHead And Neck Squamous Cell CarcinomaKostareli et al., 2013
BCIP2AEXPRESSIONPrognosticSupportsPoor OutcomePancreatic Ductal AdenocarcinomaXu et al., 2016
DCIP2AUnderexpressionPredictiveSupportsSensitivity/ResponsePancreatic Ductal AdenocarcinomaGemcitabineXu et al., 2016
BMIR218-1EXPRESSIONPrognosticSupportsBetter OutcomeColorectal CancerLi et al., 2015
BMIR218-1EXPRESSIONPrognosticSupportsBetter OutcomeColorectal CancerLi et al., 2015
CERBB2Y772_A775DUPPredictiveSupportsSensitivity/ResponseLung AdenocarcinomaTrastuzumab EmtansineWeiler et al., 2015
BEGFRVIIIPredictiveSupportsSensitivity/ResponseGlioblastomaGefitinib,ErlotinibMellinghoff et al., 2005
BPTENExpressionPredictiveSupportsSensitivity/ResponseGlioblastomaErlotinib,GefitinibMellinghoff et al., 2005
DKRASMutationPredictiveSupportsSensitivity/ResponseCancerG-573,MEK Inhibitor GDC-0623Hatzivassiliou et al., 2013
DBRAFV600EPredictiveSupportsSensitivity/ResponseCancerCobimetinibHatzivassiliou et al., 2013
DSTK11LossPredictiveSupportsResistanceLung Non-small Cell CarcinomaDocetaxel,SelumetinibChen et al., 2012
DTP53MutationPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaSelumetinib,DocetaxelChen et al., 2012
DTP53LossPredictiveSupportsResistanceLung Non-small Cell CarcinomaDocetaxelChen et al., 2012
BTP53WildtypePredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaAdjuvant ChemotherapyMa et al., 2016
CHAVCR2OverexpressionPredictiveSupportsResistanceLung Non-small Cell CarcinomaPD1 InhibitorKoyama et al., 2016
DHAVCR2OverexpressionPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaAnti-TIM-3 Monoclonal Antibody,PD1 InhibitorKoyama et al., 2016
Page 33 of 96
PreviousNext